Nanoscope Therapeutics Inc. expects to advance the therapy by launching a late-stage Phase 2b trial this summer with gene therapy that delivers multi-characteristic opsin to retinal cells.
OT Staff Reports
Advertisement
Articles by OT Staff Reports
According to the company, preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gland injection of an adeno-associated virus containing the NGF gene produced statistically significant increase in NGF in tear film, as compared to placebo, as early as Day 7.
Advertisement
Latest Updated Articles
Enriched Tear Film Gene Therapy Shows Promise for Ocular Surface DiseasesPublished: June 3rd 2021 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial
2
Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years
3
Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025
4
